Grifols (NASDAQ:GRFS) Lowered to "Buy" Rating by Wall Street Zen

Grifols (NASDAQ:GRFS - Get Free Report) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a report released on Sunday.

Separately, JPMorgan Chase & Co. lifted their price target on shares of Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research note on Tuesday, June 17th.

Grifols Stock Performance

Grifols stock opened at $8.86 on Friday. Grifols has a 12-month low of $6.19 and a 12-month high of $9.96. The company has a market capitalization of $6.09 billion, a price-to-earnings ratio of 7.57, a price-to-earnings-growth ratio of 0.32 and a beta of 0.53. The company has a debt-to-equity ratio of 1.13, a current ratio of 2.60 and a quick ratio of 0.97. The firm's fifty day moving average price is $8.05 and its 200 day moving average price is $7.65.

Hedge Funds Weigh In On Grifols

A number of hedge funds have recently bought and sold shares of GRFS. Charles Schwab Investment Management Inc. increased its holdings in Grifols by 5.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock valued at $247,000 after buying an additional 1,657 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Grifols in the fourth quarter valued at about $91,000. Highland Peak Capital LLC increased its holdings in Grifols by 29.5% in the fourth quarter. Highland Peak Capital LLC now owns 786,210 shares of the biotechnology company's stock valued at $5,849,000 after buying an additional 179,114 shares during the last quarter. HighTower Advisors LLC increased its holdings in Grifols by 28.3% in the fourth quarter. HighTower Advisors LLC now owns 17,866 shares of the biotechnology company's stock valued at $133,000 after buying an additional 3,936 shares during the last quarter. Finally, Fore Capital LLC bought a new stake in Grifols in the fourth quarter valued at about $967,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.